HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Core Viewpoint - Hims & Hers Health faced significant stock decline due to regulatory pressures, particularly after pulling its semaglutide weight-loss pill following legal threats from Novo Nordisk and the FDA, despite strong revenue growth and subscriber expansion [2][7]. Financial Performance - Q3 revenue surged 49% year-over-year to $599 million, exceeding estimates [7][8]. - The subscriber base grew by 21% to 2.5 million users, indicating strong customer acquisition [7][8]. - Adjusted EBITDA increased by 53% to $78.4 million, reflecting improved operational efficiency [8]. Market Reaction - Shares of Hims & Hers dropped 22% at market open on February 9, following the announcement of the regulatory action [2][7]. - The stock has experienced a 43% decline over the past year and a 35% drop in the last month, with technical indicators suggesting oversold conditions [3]. Investor Sentiment - Activity on Reddit's r/WallStreetBets surged, with discussions around the stock's regulatory challenges and potential recovery, showing a sentiment score rebounding to 70 [4][5]. - The most engaged post regarding the company's regulatory issues received significant interaction, indicating heightened interest among retail traders [4].